• Relmada appointed Michael Quirk as senior advisor for its sepranolone program on June 11, 2026.
• Quirk brings more than 20 years in neuroscience drug discovery and development; he previously served as chief scientific officer at Sage Therapeutics.
• He will advise development strategy for sepranolone, a GABA-A receptor modulator program targeting Prader-Willi syndrome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606110700PRIMZONEFULLFEED9735129) on June 11, 2026, and is solely responsible for the information contained therein.